Glyxambi 10 5?

Glyxambi is a fixed-dose combination tablet that contains:
- Empagliflozin 10 mg
- Linagliptin 5 mg

So, yes—Glyxambi 10/5 refers to 10 mg of empagliflozin with 5 mg of linagliptin per tablet.

Key points:
- Usual dosing: one tablet by mouth once daily, with or without food.
- How it’s used: for adults with type 2 diabetes to improve glycemic control, typically when a combo of an SGLT2 inhibitor (empagliflozin) and a DPP-4 inhibitor (linagliptin) is appropriate.
- Important cautions: not for type 1 diabetes or diabetic ketoacidosis. Use with caution in people with significant kidney impairment; your doctor will assess kidney function before and during treatment.
- Common side effects: increased urination, genital yeast infections, urinary tract infections, and sometimes nasopharyngitis. DPP-4 inhibitors can rarely cause pancreatitis; SGLT2 inhibitors can increase the risk of dehydration and genital infections.
- Interaction notes: may increase the risk of hypoglycemia if used with insulin or sulfonylureas; discuss all meds you take with your clinician.

If you were asking about a different dose or have a specific question (e.g., how it compares to separate empagliflozin and linagliptin therapy, or side effects you’re experiencing), tell me and I’ll tailor the info. If you’re considering starting Glyxambi, please consult your doctor or pharmacist for advice based on your health history.